7 completed, 2 unknown, 1 terminated, 1 withdrawn. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow Central Retinal Vein Occlusion: new trials by email Literature Review of Central Retinal Vein Occlusion trials Research Report on Central Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy - Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | The Emmes Company, LLC | 16 | 2019-10-22 | 2024-12-02 |
| Surgical Stabilizer Assisted RVC With rtPA for CRVO Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg., Intravenous Infusion - Central Retinal Vein Occlusion | Phase 1 | Withdrawn | Universitaire Ziekenhuizen KU Leuven | 2018-10-16 | 2023-03-23 | |
| Phase I RVC With Ocriplasmin for CRVO Ocriplasmin intravenously - Central Retinal Vein Occlusion | Phase 1 | Completed | Universitaire Ziekenhuizen KU Leuven | 4 | 2016-12-01 | 2018-01-08 |
| Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I ziv-aflibercept drug - Age Related Macular Degeneration, Central Retinal Vein Occlusion | Phase 1 | Unknown | Rafic Hariri University Hospital | 100 | 2014-06-01 | 2014-06-25 |
| Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Intravitreal Aflibercept Injection - Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy | Phase 1 / Phase 2 | Completed | Ophthalmic Consultants of Boston | 24 | 2012-11-01 | 2015-05-22 |
| Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion Tissue Plasminogen Activator - Central Retinal Vein Occlusion | Phase 1 | Completed | Weill Medical College of Cornell University | 1 | 2012-01-01 | 2018-08-06 |
| Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab ranibizumab 0.5mg, ranibizumab 1.0mg - Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion | Phase 1 / Phase 2 | Completed | Hanscom, Thomas, M.D. | 14 | 2011-11-01 | 2015-04-29 |
| Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion Ranibizumab (Lucentis) - Central Retinal Vein Occlusion | Phase 1 | Completed | California Retina Consultants | 20 | 2010-01-01 | 2013-12-12 |
| Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion ranibizumab (Lucentis) - Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion | Phase 1 | Unknown | Retina Associates of Cleveland, Inc | 45 | 2009-11-01 | 2011-03-18 |
| Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion FOV2302 (Ecallantide) - Macular Edema, Central Retinal Vein Occlusion | Phase 1 | Terminated | Fovea Pharmaceuticals SA | 11 | 2009-09-01 | 2012-01-10 |
| Lucentis for Central Retinal Vein Occlusion (CRVO) Ranibizumab - Central Retinal Vein Occlusion | Phase 1 | Completed | California Retina Consultants | 20 | 2006-01-01 | 2013-12-12 |
Retinal Vein Occlusion (11) · Macular Edema (3) · Depression (1) · Eye Diseases (1) · Macular Degeneration (1) · Retinal Diseases (1) · Vision Disorders (1)
Cardiovascular Diseases (11) · Embolism and Thrombosis (11) · Thrombosis (11) · Vascular Diseases (11) · Venous Thrombosis (11) · Eye Diseases (10) · Retinal Diseases (10) · Retinal Degeneration (4) · Macular Degeneration (3) · Behavior (1) · Behavioral Symptoms (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Sensation Disorders (1)
Ranibizumab (4) · Tissue Plasminogen Activator (2) · Infusions, Intravenous (1) · Plasminogen (1) · Vitrectomy (1) · aflibercept (1) · ecallantide (1)
California Retina Consultants (2) · Universitaire Ziekenhuizen KU Leuven (2) · Fovea Pharmaceuticals SA (1) · Hanscom, Thomas, M.D. (1) · Ophthalmic Consultants of Boston (1) · Rafic Hariri University Hospital (1) · Retina Associates of Cleveland, Inc (1) · The Emmes Company, LLC (1) · Weill Medical College of Cornell University (1)
United States (7) · Belgium (2) · France (1) · Lebanon (1)
Ahmad Mansour, MD (1) · Alain Gaudric, MD (1) · Dante J Pieramici, M.D. (1) · Dante J Pieramici, MD (1) · Jeffrey S Heier, MD (1) · Lawrence J Singerman, MD (1) · Peter Stalmans (1) · Peter Stalmans, MD PhD (1) · Susanna S Park, MD, PhD (1) · Thomas O'Hearn, MD (1) · Y Pierre Gobin, MD (1)
1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1)